CD8A and breast cancer: Here, we report that a single dose of an NKT cell‐activating glycolipid‐peptide conjugate vaccine can generate cytotoxic CD8+ T‐cell responses, delay tumor growth in vivo and prevent tumor colonisation of the lung in models of breast cancer metastasis.